Open Access and Free to Publish in Progress in Stem Cell

Letter to Editor Open Access Logo

Expanded mesenchymal stem cell transplantation is safe in both local injection and vein transfusion

Vlassov V Salval 1, *
Yone Moto 2
  1. Cell Therapy Centre, Russia
  2. Stem Cell Therapy Centre, Russia
Correspondence to: Vlassov V Salval, Cell Therapy Centre, Russia. Email: salvalvlassov@gmai.com.
Volume & Issue: Vol. 4 No. 3-4 (2017) | Page No.: 227-228 | DOI: 10.15419/psc.v4i3-4.398
Published: 2017-12-29

Online metrics


Statistics from the website

  • HTML Views: 9031
  • PDF Views: 1298
  • XML Views: 3

Statistics from Dimensions

Copyright The Author(s) 2017. This article is published with open access by BioMedPress. This article is distributed under the terms of the Creative Commons Attribution License (CC-BY 4.0) which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited. 

Abstract

More than 500 clinical trials are using mesenchymal stem cells (MSCs) in the world to treat some different diseases. The safety of expanded MSC transplantation is the most important thing to ensure that this therapy can become the routine treatment of human illnesses. More than five MSCs based stem cell drug products are approved in various countries demonstrated that expanded MSCs are safe in both local injection and transfusion. Moreover, some recent reports for six years followed-up clinical trials using expanded MSCs confirmed that there is not different tumorigenesis between the patients with and without expanded MSC transplantation. This letter aims to provide some evidence about the safety of expanded MSCs in clinical applications. However, the MSC quality should be strictly controlled during the in vitro MSC expansion.

Abstract

More than 500 clinical trials are using mesenchymal stem cells (MSCs) in the world to treat some different diseases. The safety of expanded MSC transplantation is the most important thing to ensure that this therapy can become the routine treatment of human illnesses. More than five MSCs based stem cell drug products are approved in various countries demonstrated that expanded MSCs are safe in both local injection and transfusion. Moreover, some recent reports for six years followed-up clinical trials using expanded MSCs confirmed that there is not different tumorigenesis between the patients with and without expanded MSC transplantation. This letter aims to provide some evidence about the safety of expanded MSCs in clinical applications. However, the MSC quality should be strictly controlled during the in vitro MSC expansion.

1. Dear Editor-in-Chief

In 2017, more than ten publications used expanded to treat some diseases in both local injection and infusion in Pubmed [ 1–10 ]. All publications showed expanded MSC transplantation was safe. Some studies followed-up 12 months, others followed up to 6 years. And some transplantations are autologous, and others are allogeneic. In the recent report, Bartolucci et al. (2017) infused allogenic expanded MSCs from umbilical cord tissue at the dose of 1 106 cells/kg to treat heart failure and follow-up to 12 months [ 1 ]. At 12th months, only UC-MSC treated group significantly improved the left ventricular ejection fraction. More importantly, there were no differences in mortality, heart failure admissions, arrhythmias, or incident malignancy between treatment group and placebo group [ 1 ]. In another study, Pang et al. (2017) reported the results of the clinical trial using the allogenic expanded MSCs from bone marrow for aplastic anemia treatment [ 8 ]. After the median follow-up of 17 months, the overall survival was 87.8%; there were 7/74 patients developed a mild headache and fever, no other side effects were detected. With these results, authors confirmed that allogenic BM-derived MSCs are safe in aplastic anemia [ 8 ].

In India, a four year-follow up study used autologous expanded MSC from bone marrow to treat chronic stroke [ 9 ]. In this study, 12 chronic stroke patients were intravenously infused with autologous expanded MSCs. All patients were followed up the 208th week without any cell related side effects [ 9 ].

For local injection, two clinical trials using expanded MSCs with one clinical trial followed up six years were reported. Centeno et al. (2017) lumbar degenerative disc disease-associated radicular pain with autologous expanded MSCs. In this study, thirty-three patients injected with their expanded MSCs and followed up to 6 years post-treatment. There was no any severe side effect such as death, infection, and tumor in the patients related to MSC transplantation. Particularly, up to 85% patients had a reduction in disc bulge size with average reduction size of 23% post-treatment [ 2 ].

I also found another report about safety and efficacy of Cx601 products in the treatment of complex perianal fistulas in Crohn’s disease [ 3 ]. This study was funded by TiGenix to investigate the effectiveness of Cx601 – a stem cell drug containing allogenic adipose tissue-derived stem cells. The patients would be intralesionally injected with 120 million of Cx601 cells with the single injection. Patients were followed up to 52 weeks post-treatment. The results showed that 17% of patients treated with Cx601 and 29% patients in the placebo group had side effects included anal abscess and proctalgia [ 3 ].

By these reports, I initially concluded that autologous and allogenic expanded MSC transplantations are safe in both local injection and vein transfusion. However, more studies with longer time follow-up are essential to perform the meta-analysis review about the safety of expanded MSC transplantation.

2. Open Access

This article is distributed under the terms of the Creative Commons Attribution License (CC-BY 4.0) which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.

3. List of abbreviations

BM: Bone marrow; MSCs: Mesenchymal stem cells; UC: Umbilical cord

4. Ethics approval and consent to participate

Not to be applied

5. Competing interests

The authors declare that no competing interests exist.

6. Funding

Not to be applied

7. Authors contributions

Both authors equally contributed in this manuscript, from preparing idea, looking references and writing. All authors approved the final manuscript.

8. Acknowledgements

Not to be applied

References

  1. Jorge Bartolucci, FernandoJ Verdugo, PazL González, RicardoE Larrea, Ema Abarzua, Carlos Goset, Pamela Rojo, Ivan Palma, Ruben Lamich, PabloA Pedreros, Gloria Valdivia, ValentinaM Lopez, Carolina Nazzal, Francisca Alcayaga-Miranda, Jimena Cuenca, MatthewJ Brobeck, AmitN Patel, FernandoE Figueroa, Maroun Khoury. Safety and Efficacy of the Intravenous Infusion of Umbilical Cord Mesenchymal Stem Cells in Patients With Heart FailureNovelty and Significance. Circulation Research 2017-sep; : 1192-1204.
  2. Christopher Centeno, Jason Markle, Ehren Dodson, Ian Stemper, ChristopherJ Williams, Matthew Hyzy, Thomas Ichim, Michael Freeman. Treatment of lumbar degenerative disc disease-associated radicular pain with culture-expanded autologous mesenchymal stem cells: a pilot study on safety and efficacy. Journal of Translational Medicine 2017-sep; :
  3. Julián Panés, Damián García-Olmo, GertVan Assche, JeanFrederic Colombel, Walter Reinisch, DanielC Baumgart, Axel Dignass, Maria Nachury, Marc Ferrante, Lili Kazemi-Shirazi, JeanC Grimaud, Fernandodela Portilla, Eran Goldin, MariePaule Richard, Anne Leselbaum, Silvio Danese. Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn\textquotesingles disease: a phase 3 randomised, double-blind controlled trial. The Lancet 2016-sep; : 1281-1290.
  4. RohteshS Mehta, RimaM Saliba, Kai Cao, Indreshpal Kaur, Katy Rezvani, Julianne Chen, Amanda Olson, Simrit Parmar, Nina Shah, David Marin, Amin Alousi, Chitra Hosing, Uday Popat, Partow Kebriaei, Richard Champlin, Marcosde Lima, Donna Skerrett, Elizabeth Burke, ElizabethJ Shpall, Betul Oran. Ex Vivo Mesenchymal Precursor Cell–Expanded Cord Blood Transplantation after Reduced-Intensity Conditioning Regimens Improves Time to Neutrophil Recovery. Biology of Blood and Marrow Transplantation 2017-aug; : 1359-1366.
  5. JeffreyA Cohen, PeterB Imrey, SarahM Planchon, RobertA Bermel, Elizabeth Fisher, RobertJ Fox, Amit Bar-Or, SusanL Sharp, ThomaiT Skaramagas, Patricia Jagodnik, Matt Karafa, Shannon Morrison, JaneReese Koc, StantonL Gerson, HillardM Lazarus. Pilot trial of intravenous autologous culture-expanded mesenchymal stem cell transplantation in multiple sclerosis. Multiple Sclerosis Journal 2017-apr; : 501-511.
  6. Eva Syková, Petr Rychmach, Ivana Drahorádová, ŠImona Konrádová, KateŖina R\ru\vzičková, Ivan VoŖíšek, Serhiy Forostyak, Aleš Homola, Martin Bojar. Transplantation of Mesenchymal Stromal Cells in Patients with Amyotrophic Lateral Sclerosis: Results of Phase I/IIa Clinical Trial. Cell Transplantation 2017-apr; : 647-658.
  7. Jens Kastrup, Mandana Haack-Sørensen, Morten Juhl, RebekkaHarary Søndergaard, Bjarke Follin, LisbethDrozd Lund, EllenMønsted Johansen, AbbasAli Qayyum, AndersBruun Mathiasen, Erik Jørgensen, Steffen Helqvist, JensJørgen Elberg, Helle Bruunsgaard, Annette Ekblond. Cryopreserved Off-the-Shelf Allogeneic Adipose-Derived Stromal Cells for Therapy in Patients with Ischemic Heart Disease and Heart Failure-A Safety Study. STEM CELLS Translational Medicine 2017-sep; : 1963-1971.
  8. Yan Pang, Hao-Wen Xiao, Hang Zhang, Zeng-Hui Liu, Li Li, Yang Gao, Hong-Bo Li, Zu-Jun Jiang, Huo Tan, Jing-Ren Lin, Xin Du, Jian-Yu Weng, Da-Nian Nie, Dong-Jun Lin, Xiang-Zhong Zhang, Qi-Fa Liu, Duo-Rong Xu, Hai-Jia Chen, Xiao-Hu Ge, Xiao-Yan Wang, Yang Xiao. Allogeneic Bone Marrow-Derived Mesenchymal Stromal Cells Expanded In Vitro for Treatment of Aplastic Anemia: A Multicenter Phase II Trial. STEM CELLS Translational Medicine 2017-may; : 1569-1575.
  9. Ashu Bhasin, MVPadma Srivastava, SSenthil Kumaran, Sujata Mohanty, Rohit Bhatia, Sushmita Bose, Shailesh Gaikwad, Ajay Garg, Balram Airan. Autologous Mesenchymal Stem Cells in Chronic Stroke. Cerebrovascular Diseases Extra 2011; : 93-104.
  10. Yong-Beom Park, Chul-Won Ha, Choong-Hee Lee, YoungCheol Yoon, Yong-Geun Park. Cartilage Regeneration in Osteoarthritic Patients by a Composite of Allogeneic Umbilical Cord Blood-Derived Mesenchymal Stem Cells and Hyaluronate Hydrogel: Results from a Clinical Trial for Safety and Proof-of-Concept with 7 Years of Extended Follow-Up. STEM CELLS Translational Medicine 2016-sep; : 613-621.

Comments